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Abstract
Background: This study was designed to investigate the efficacy and safety of the epidermal
growth factor receptor (EGFR) inhibitor cetuximab combined with irinotecan, folinic acid (FA) and
two different doses of infusional 5-fluorouracil (5-FU) in the first-line treatment of EGFR-detectable
metastatic colorectal cancer.
Methods: The 5-FU dose was selected on the basis of dose-limiting toxicities (DLTs) during part
I of the study. Patients received cetuximab (400 mg/m2 initial dose and 250 mg/m2/week thereafter)
and every 2 weeks irinotecan (180 mg/m2), FA (400 mg/m2) and 5-FU (either low dose [LD], 300
mg/m2 bolus plus 2,000 mg/m2 46-hour infusion, n = 7; or, high-dose [HD], 400 mg/m2 bolus plus
2,400 mg/m2; n = 45).
Results: Only two DLTs occurred in the HD group, and HD 5-FU was selected for use in part II.
Apart from rash, commonly observed grade 3/4 adverse events such as leucopenia, diarrhoea,
vomiting and asthenia occurred within the expected range for FOLFIRI. Among 52 patients, the
overall response rate was 48%. Median progression-free survival (PFS) was 8.6 months (counting
all reported progressions) and the median overall survival was 22.4 months. Treatment facilitated
the resection of initially unresectable metastases in fourteen patients (27%): of these, 10 patients
(71%) had no residual tumour after surgery, and these resections hindered the estimation of PFS.
Conclusion: The combination of cetuximab and FOLFIRI was active and well tolerated in this
setting. Initially unresectable metastases became resectable in one-quarter of patients, with a high
number of complete resections, and these promising results formed the basis for the investigation
of FOLFIRI with and without cetuximab in the phase III CRYSTAL trial.
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Background
Worldwide, colorectal cancer (CRC) is the third most
commonly diagnosed malignancy.[1] In Europe alone in
2006, there were an estimated 412,900 new cases and
over 207,000 deaths from the disease.[2] The addition of
irinotecan[3,4] or oxaliplatin[5,6] to 5-FU/FA-based regi-
mens, has improved the efficacy of treatment. Combina-
tions of irinotecan and 5-FU/FA have increased overall
survival (OS) times to approximately 20 months.[3,4,7,8]
These improvements in efficacy, however, have come at a
price of increased toxicity. Diarrhoea and neutropenia are
commonly observed with irinotecan-based regimens,
although they are generally manageable.[3]
A positive correlation between tumour response rate and
metastatic resection rate, has been demonstrated in meta-
static CRC (mCRC) patients receiving neoadjuvant chem-
otherapy.[9] Resection remains the best chance of cure,
with five-year survival rates of up to 60% having been
reported in carefully selected patients.[10] With the
advent of more effective chemotherapy and a correspond-
ing improvement in response rates, the incidence of com-
plete resection is increasing. New therapeutic options,
which will increase both the magnitude of response and
the number of responders, to render incurable disease cur-
able, are being sought. [11-15]
Cetuximab, an IgG1 monoclonal antibody, specifically
targets the epidermal growth factor receptor (EGFR) with
high affinity. The EGFR is widely expressed by a range of
tumours, including CRC [16-18] where it has been
reported to be associated with a slightly poorer progno-
sis.[19,20] Cetuximab blockade of EGFR results in inhibi-
tion of tumour growth, invasion, metastasis and
angiogenesis. [21-23] Cetuximab has demonstrated effi-
cacy benefits in patients with mCRC that have progressed
on irinotecan-containing therapy, either in combination
with irinotecan[16,24] or as a single agent.[18,25]
This two-part, phase I/II study was designed to evaluate
the safety and efficacy of cetuximab in combination with
FOLFIRI in CRC patients with previously untreated unre-
sectable metastatic disease, and to define a dosing regi-
men for further investigation exploring two different
doses of 5-FU.
Methods
Eligibility criteria
Patients ≥18 years of age were eligible for study entry if
they had: histologically confirmed stage IV colorectal ade-
nocarcinoma with unresectable metastases, immunohis-
tochemically detectable EGFR expression in the primary
tumour or metastases; ≥ one uni-dimensionally measura-
ble lesion outside irradiated areas, a life expectancy of ≥3
months; a Karnofsky Performance Status (KPS) of ≥60;
completion of previous adjuvant chemotherapy >4 weeks
prior to study entry and recovery from the effects of previ-
ous chemotherapy/radiotherapy; adequate haematologi-
cal, renal and hepatic function. The main exclusion
criteria were: radiotherapy or surgery <4 weeks prior to
study entry; any previous chemotherapy for mCRC; and
evidence of brain metastases.
The protocol, and any protocol amendments, for this
multicentre study were approved by independent ethics
committees for each centre. The study was conducted in
accordance with the Declaration of Helsinki (1996). All
patients provided written informed consent.
Study design
This was a multicentre, uncontrolled, open-label, two-
part, phase I/II study, which enrolled patients between
October 2001 and June 2003. All patients received 2-
weekly cycles of a combination of weekly cetuximab and
2-weekly chemotherapy, comprising irinotecan and either
high-dose (HD, 2,800 mg/m2) or low-dose (LD, 2,300
mg/m2) 5-FU and FA. In the initial part of the study,
cohorts of patients were sequentially assigned to treat-
ment with either LD or HD 5-FU. Patients benefiting from
treatment (at least stable disease [SD]) after 3 cycles (6
weeks, phase A) continued with the treatment at the same
dose of 5-FU until disease progression (PD) or unaccept-
able toxicity (phase B, Figure 1). The choice of 5-FU dose
for additional patients in part II of the study was based on
the evaluation of dose-limiting toxicities (DLTs) observed
in phase A of part I. Patients showing a benefit (at least
stable disease [SD]) after 3 cycles of treatment, continued
combination therapy until PD or unacceptable toxicity.
Patients benefiting from combination therapy, but with
unacceptable secondary intolerance to irinotecan and/or
5-FU/FA, could receive single-agent cetuximab until unac-
ceptable toxicity or PD.
Objectives
The primary objective of the study was to define the high-
est safe dose of intermittent infusional 5-FU out of the two
given doses in combination with cetuximab and irinote-
can for the first-line therapy of mCRC, based on DLTs and
adverse events. The secondary objectives included the
evaluation of: best overall response, which was defined as
the best confirmed response (Response Evaluation Crite-
ria in Solid Tumors [RECIST] criteria: complete response,
CR, or partial response, PR, persisting ≥28 days) from the
start of treatment until PD; duration of response (the time
from the first assessment of a confirmed CR or PR to the
first documentation of PD, or death on study, death
within 60 days after the last tumour assessment or the first
dose of cetuximab, whichever occurred first); all responses
were reviewed by one investigator (P. Rougier). Progres-
sion-free survival time (PFS) was also evaluated (the timeBMC Cancer 2009, 9:112 http://www.biomedcentral.com/1471-2407/9/112
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from the first dose of cetuximab until the first observation
of PD or death due to any cause within 60 days after the
last tumour assessment). In this PFS estimation, the
patients who benefited from secondary surgery for metas-
tases were censored at the date of the surgery, although
none had PD at this date. Censoring of patients due to
study discontinuation for reasons other than PD (due to
planned resection of residual disease or other reasons)
was termed informative censoring. We subsequently
defined a progression/recurrence-free survival (PRFS)
time, which used the date of recurrence after surgery as the
date of progression for the resected patients. The OS time
was also a secondary objective (the time from the day of
the first dose of cetuximab to death).
Treatment
Cetuximab was administered intravenously (iv) as an ini-
tial 2-hour infusion of 400 mg/m2 (day 1), including a test
dose of 20 mg, followed by weekly 1-hour infusions of
250 mg/m2. Irinotecan, 5-FU and FA were administered 2-
weekly. Irinotecan (180 mg/m2 iv) was administered at
least 1 hour after the end of the cetuximab infusion. FA
(400 mg/m2 iv) was administered as a 2-hour infusion on
day 1, prior to 5-FU infusion. 5-FU was administered fol-
lowing irinotecan and FA at one of two doses: LD, 300
mg/m2 bolus plus 2,000 mg/m2 as a continuous 46-hour
infusion; HD, 400 mg/m2 bolus plus 2,400 mg/m2 as a
continuous 46-hour infusion.
Study design Figure 1
Study design.BMC Cancer 2009, 9:112 http://www.biomedcentral.com/1471-2407/9/112
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Assignment to dosing levels – part I
Two dose levels for 5-FU were considered: LD 5-FU and
HD 5-FU. Cohorts of six patients were enrolled starting
with LD 5-FU. A cohort with HD 5-FU was to be started if
fewer than three DLTs were observed during the first 6
weeks (phase A-DLT evaluation period) (see Figure 2 for
details of the 5-FU escalation procedure). If three or four
DLTs were observed in the LD cohort, another cohort of
six patients was enrolled into the LD group and if more
than four DLTs occurred, then the trial had to be stopped
(Figure 2). If more than two DLTs occurred in the first HD
cohort, another cohort of LD 5-FU was started. If not more
than two patients experienced a DLT in the first HD
cohort, another HD cohort was started. If more than four
patients experienced DLTs under HD after two cohorts of
HD, patients were enrolled in another LD cohort. During
phase A, additional patients had to be recruited to replace
patients who discontinued for reasons other than toxicity
prior to completion of phase A.
Dosing modifications
In the case of grade 3 skin reactions, cetuximab could be
interrupted for up to two consecutive infusions. After an
infusion delay of 1 week and following resolution of
symptoms to ≤grade 2, cetuximab could be resumed at the
same dose in patients experiencing their first occurrence
of grade 3 skin toxicity or at a reduced dose of 200 or 150
mg/m2 (for second and third occurrences, respectively).
Treatment in these patients was discontinued in the event
of a fourth occurrence of a grade 3 reaction. In patients
with grade 3 skin reactions that failed to resolve to ≤grade
2 following an initial infusion delay of 1 week, patients
could delay treatment for a further week but were discon-
tinued if more than two consecutive infusions were
delayed, or if there was any further occurrence of grade 3
skin toxicity during treatment. Cetuximab-associated
infusion-related reactions were managed as follows: grade
1/2, increase of infusion time up to 4 hours and, if this
had no effect, consider patient withdrawal from the study;
grade 3/4, immediate cessation of cetuximab infusion and
patient withdrawal from study.
Treatment was delayed by 1 to 2 weeks to allow for recov-
ery from chemotherapy-associated toxicities. Dose reduc-
tions of irinotecan and 5-FU were made for toxicities
including: neutropenia (>grade 3), febrile neutropenia,
thrombocytopenia or other organ toxicity (>grade 2),
mucositis, diarrhoea, or constipation (>grade 1). Dose
reductions of 5-FU were made for hand-foot syndrome
(HFS) >grade 2.
Dose-limiting toxicities
The DLT evaluation period was limited to the first 6 weeks
of treatment in part I, phase A of the study. A DLT was
defined as the occurrence of at least one of the following
toxicities according to National Cancer Institute-Com-
mon Toxicity Criteria (NCI-CTC) version 2.0: grade 4 neu-
tropenia, leucopenia or thrombocytopenia; > grade 3 skin
reactions; > grade 2 febrile neutropenia, infection with
neutropenia, anaemia, diarrhoea, mucositis, hepatic tox-
icity, creatinine levels, or any other medically relevant
treatment-related organ toxicity; any drug-related adverse
event/s which required treatment interruption.
Pre-treatment assessments and response and toxicity 
evaluations
EGFR expression was determined by an independent
pathologist using the Dako EGFR pharmDx™ (Dako,
Glostrup, Denmark) on tumour tissue available prior to
the study. Tumours were considered EGFR-detectable if
any tumour cell demonstrated any expression of the
receptor. Independently of DLTs, adverse events, graded
according to NCI-CTC version 2.0, were recorded
throughout the study. Tumour response was based on
investigator tumour measurements (reviewed by the prin-
cipal investigator) of target and non-target lesions, using
computed tomography (CT) or magnetic resonance imag-
ing (MRI). The same imaging technique was to be used in
the same patient throughout the study. Imaging was per-
formed at baseline, at weeks 6 and 12 and then every 3
months.
Statistical analyses
Three populations are described: the DLT population (ie
all patients from part I who completed the first 3 cycles
[phase A] or who stopped treatment because of a DLT);
the intention-to-treat (ITT) population (all patients
included in the study); and the safety population (all
Dose assignment scheme to LD and HD 5-FU in part I Figure 2
Dose assignment scheme to LD and HD 5-FU in part 
I.
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patients who received at least one dose of cetuximab).
Assessment of the primary study objective was performed
on the DLT population. Adverse events recorded in part I,
phase A of the study were also included in the overall
adverse event assessments. Efficacy results were based on
investigators' assessments of patients in the ITT popula-
tion. Continuous variables were summarised using
descriptive statistics (N, mean, median, standard devia-
tion, minimum, maximum, and first and third quartile).
Qualitative variables were summarised by counts and per-
centages. Kaplan-Meier methods were applied to all time-
to event variables. All data were pooled across centres and
overall estimates of the treatment effects are provided. No
formal statistical tests were performed.
As a substantial number of patients were censored for PFS
(56%), sensitivity analysis of the PFS time of these
patients was performed, and we have estimated the PRFS
time, which included follow-up data. As documentation
of a PD date was available in the follow-up period for
most of the patients, all follow-up data underwent a thor-
ough review of additional information, such as second-
line treatment and treatment after surgery to explore evi-
dence of PD before the reporting date. A PD was consid-
ered as an event for this analysis if the date was given
before the start of a new line of anti-cancer treatment.
Chemotherapy administered following surgery was not
considered as a new treatment line.
Results
Patient characteristics
A total of 52 patients were enrolled in the study (23 in part
I and 29 in part II) and comprise the ITT and safety popu-
lations: seven received LD 5-FU and 45 received HD 5-FU.
There were 23 patients in the DLT population in part I,
phase A (n = 7, LD 5-FU; n = 16, HD 5-FU). There were
three major protocol violations in part I, as a result of
which two patients were replaced for DLT evaluation.
However, one patient enrolled into the HD 5-FU group
received LD 5-FU for 7 cycles and subsequently received
the correct HD 5-FU and was therefore included as an
addition to the initially planned number of six patients in
this group. Baseline demographic and pre-treatment char-
acteristics were similar in the two dose groups (Table 1).
All patients discontinued study treatment. Three patients
received cetuximab after the end of study discontinuation
of chemotherapy. The most common reason for discon-
tinuation of treatment was PD (35%). However, a high
proportion of patients (27%) discontinued study treat-
ment without PD due to the fact that treatment had ren-
dered their initially unresectable disease operable,
Table 1: Patient and disease characteristics and prior treatments
Characteristics LD 5-FU (n = 7) HD 5-FU (n = 45) Total (n = 52)
Gender, M/F (%) 57/43 64/36 63.5/36.5
Median age, years [range] 66 [49–73] 61 [25–77] 61 [25–77]
Median KPS [range] 100 [80–100] 100 [60–100] 100 [60–100]
Median duration of disease, months [range] 1.4 [1–25] 1.5 [0–84] 1.5 [0–84]
Primary tumour site (%):
Colon 86 67 69
Rectum 14 33 31
Previous adjuvant chemotherapy (%) 14 20 19
Number of involved organs (%) ≤ 2 100 93 94
Normal WBC at baseline (%) 100 96 96
Normal LDH at baseline (%) 57 49 50
Normal ALP at baseline (%) 29 36 35
EGFR status (%):a
0–≤10 43 42 42
>10–≤20 14 13 14
>20–≤35 29 13 15
>35 14 31 29
aPercentage of positive cells; LD = low-dose; HD = high-dose; KPS = Karnofsky Performance Status; WBC = white blood cell; LDH = lactate 
dehydrogenase; ALP = alkaline phosphatase; EGFR = epidermal growth factor receptor.BMC Cancer 2009, 9:112 http://www.biomedcentral.com/1471-2407/9/112
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allowing surgery of the residual lesions. Three patients
(6%) discontinued due to adverse events (one with LD 5-
FU and two with HD 5-FU).
Treatment
Assessment of the relative dose intensity (RDI) showed
that RDIs of ≤80% were recorded for most patients: cetux-
imab (90%), irinotecan (81%) and 5-FU (92%). A total of
83% of patients received further lines of antineoplastic
treatments after the study.
DLTs and recommended dose level
In part I, phase A of the study, no DLTs were reported in
the LD group. Two patients in the HD group experienced
DLTs (13%) (Table 2). The safety profile of HD 5-FU was
considered to be acceptable based on these results and
thus was pursued as the recommended dose in part II of
the study.
Tolerability
Treatment was generally well tolerated and adverse events
were those expected with the treatments and the underly-
ing disease. The most frequently reported adverse events
(any grade) were diarrhoea (77%), asthenia (75%), nau-
sea (67%) and rash (52%). Grade 3/4 adverse events were
reported in 65% of patients and the most frequent were
leucopenia, acne-like rash, diarrhoea, vomiting and asthe-
nia (Table 3). Cetuximab-related grade 3/4 adverse events
were reported in 48% of patients.
Serious adverse events (SAEs) were reported in 50% of
patients. Cetuximab or chemotherapy was discontinued
due to adverse events in three patients (6%). Four (8%)
patients died within the period from randomisation to 30
days after the last dose of cetuximab, two (4%) of PD, one
of disease-related liver complications, and the other of
pneumonia as an unrelated illness. There were no deaths
considered to be treatment-related.
Efficacy
In the overall study population, a best confirmed overall
response rate of 48% was reported, with rates of 57% and
47% in the LD and HD groups, respectively (Table 4). Five
(10%) additional patients had unconfirmed responses,
two (4%) of which were not confirmed because surgery of
the lesions was performed. There were no complete
responses. The disease control rates were 87%, 86% and
87%, overall and in the LD and HD groups, respectively.
The median duration of response was 9.9 months in the
overall study population, 7.7 months in the LD popula-
tion and 9.9 months in the HD population.
The median PFS was estimated as 7.9 months overall
[95% CI 5.3, 12.2] (Figure 3), and 5.8 [95% CI 2.8, NE]
and 7.9 months [95% CI 5.1, 11.8] within the LD and HD
populations, respectively. However a substantial propor-
tion of patients in this analysis (56%) did not develop
measurable PD but were subject to informative censoring
due to study discontinuation (27% due to planned resec-
tion of residual disease, 15% due to patient request for a
treatment pause following good response to treatment).
Therefore, a further exploratory analysis of PRFS, which
included follow-up data and recurrence after resection,
was performed. The proportion of censoring in this anal-
ysis decreased to 19% and the remaining censored obser-
vations were considered unlikely to be subject to
informative censoring. With the inclusion of the PRFS
into the analysis, the median PFS was found to be 8.6
months (Figure 4).
The median OS was 22.4 months [95% CI 16.5, 24.9] over
the whole population (Figure 5), and 18.1 months [95%
CI 8.7, 24.9] and 22.6 months [95% CI 16.5, 25.6] in the
LD and HD populations, respectively.
At least nine (17%) patients were still alive after a follow
up period of more than 4 years.
Complete resection of initially unresectable disease
Over one-quarter (n = 14, 27%) of patients underwent
surgery of residual disease with curative intent: 21% for
liver metastases, 2% for lung and 4% for metastases at
other sites. There was no residual tumour after surgery in
71% of these patients. Of the remaining patients, one had
Table 2: Dose-limiting toxicities in part I, phase A (DLT population)
Events No. of patients (%)
LD 5-FU (n = 7) HD 5-FU (n = 16)
No. patients with any event 0 (0) 2 (13)
Leucopenia or neutropenia grade 4 0 1 (6)
Occurrence of any drug-related AE that required treatment interruption within the first six weeks 0 1 (6)*
LD = low-dose; HD = high-dose; AE = adverse event. Seven patients were recruited in the low-dose 5-FU arm due to an overlap in the enrolment 
of two patients.*Anaphylactic reaction.BMC Cancer 2009, 9:112 http://www.biomedcentral.com/1471-2407/9/112
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microscopic and two, macroscopic residual lesions, and
the final patient was not assessable.
Discussion
The initial part of this two-part study confirmed that
weekly cetuximab could be safely combined with 2-
weekly irinotecan and the usual dose of 5-FU in the mod-
ified FOLFIRI-regimen[3,7] (400 mg/m2 bolus plus 2,400
mg/m2)/FA, which formed the high dose 5-FU-regimen of
this study. The second part of the study demonstrated that
this combination of cetuximab and the FOLFIRI regimen
was associated with promising efficacy and good tolera-
bility in the first-line treatment of mCRC. Of the 45
patients treated with the HD 5-FU regimen, 47% achieved
an objective response. The median PFS for all 52 patients,
according to an exploratory analysis adding in PD infor-
mation from the follow-up, was 8.6 months (7.9 months
according to the planned analysis with only on-study
Table 3: Grade 3/4 adverse events occurring in at least two patients in the safety population
Preferred term Number of patients Number (%) patients
LD 5-FU
(n = 7)
HD 5-FU
(n = 45)
Total
(n = 52)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Leucopenia 2 [2] 0 8 [8] [1] 10 (19) 1 (2)
Diarrhoea 0 0 6 [5] 0 6 (12) 0 (0)
Vomiting 1 [1] 0 5 [3] 0 6 (12) 0 (0)
Rash 2 [2] 0 4 [4] 0 6 (12) 0 (0)
Acne 2 [2] 0 3 [3] 0 5 (10) 0 (0)
Asthenia 2 [2] 0 3 [1] 1 5 (10) 1 (2)
Intestinal obstruction 0 0 4 1 4 (8) 1 (2)
Abdominal pain 0 0 3 0 3 (6) 0 (0)
Mucous membrane disorder 0 0 3 [3] 0 3 (6) 0 (0)
Dyspnoea 0 0 3 [3] 1 3 (6) 1 (2)
Atrial fibrillation 0 0 2 0 2 (4) 0 (0)
Deep thrombophlebitis 0 0 2 [1] 0 2 (4) 0 (0)
Gamma glutamyl transpeptidase increased 0 0 2 [1] 0 2 (4) 0 (0)
Hypokalaemia 0 0 2 0 2 (4) 0 (0)
Liver function test abnormal 0 0 2 [1] 0 2 (4) 0 (0)
Skin disorder 0 0 2 [2] 0 2 (4) 0 (0)
Thrombosis 0 0 2 0 2 (4) 0 (0)
Urinary tract infection 0 0 2 0 2 (4) 0 (0)
Weight loss 0 0 2 [1] 0 2 (4) 0 (0)
Square brackets indicate the number of events related to study treatment. LD = low-dose; HD = high-dose.BMC Cancer 2009, 9:112 http://www.biomedcentral.com/1471-2407/9/112
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Progression-free survival time – ITT population Figure 3
Progression-free survival time – ITT population.
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Table 4: Response (ITT population)
LD 5-FU (n = 7) HD 5-FU (n = 45) Total (n = 52)
Response rate (%)
Best overall response rate [95% CI]a 57
[18, 90]
47
[32, 62]
48
[34, 62]
Stable disease 29 40 39
Progressive disease 14 9 10
Not assessable 0 4 4
Disease control rate (CR + PR + SD) (%) [95% CI] 86
[42, 100]
87
[73, 95]
87
[74, 94]
Median duration of response, days [95% CI] 7.7
[2.9, 12.2]
9.9
[8.1, 13.6]
9.9
[8.1, 11.4]
aAll partial responses. LD = low-dose 5-FU; HD = high-dose 5-FU; CI = confidence intervals; CR = complete response; PR = partial response; SD = 
stable diseaseBMC Cancer 2009, 9:112 http://www.biomedcentral.com/1471-2407/9/112
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events). The survival time of 22.4 months reported in this
study is favourable compared with those reported for dif-
ferent schedules of FOLFIRI alone in the first-line treat-
ment of patients with mCRC (17.4 months and 20.1
months), many of whom received similar second-line
therapy (FOLFOX and FOLFIRI) to the patients in this
study.[3,7] The survival time also compares well with the
20.3 months reported by adding the vascular endothelial
growth factor (VEGF) inhibitor, bevacizumab, to first-line
bolus irinotecan/5-FU/FA.[26]
In the present study, treatment was generally well toler-
ated. The majority of patients were able to receive more
than 80% of the planned dose of each drug and there were
no treatment-related deaths. The addition of cetuximab to
the 2-weekly regimen of FOLFIRI induced few additional
side effects and did not aggravate the typical grade 3/4 tox-
icities associated with this chemotherapeutic regimen.
The data from this study, suggesting the benefits of adding
cetuximab to combinations of irinotecan and 5-FU in the
first-line treatment of mCRC, are supported by results
from two other phase I/II studies. In an initial study, the
combination of cetuximab with irinotecan (125 mg/m2/
week) and bolus 5-FU (500 mg/m2/week)/leucovorin led
to an overall response rate of 48% [95% CI 29, 68].[27]
The most frequently reported grade 3/4 adverse events
were diarrhoea and neutropenia (28% for each). More
recently, Folprecht et al[17] investigated the tolerability
and safety of cetuximab with a combination of irinotecan
and the AIO weekly infusional 5-FU/FA regimen in a
phase I/II trial in 21 patients with previously untreated,
EGFR-detectable mCRC. 5-FU was administered weekly as
a 24-hour infusion at low (1,500 mg/m2, n = 6) or high
(2,000 mg/m2, n = 15) doses, with FA at 500 mg/m2 and
irinotecan at 80 mg/m2. The lower 5-FU dose of 1,500
mg/m2 was recommended for future investigation. A con-
firmed response was reported for 67% [95% CI 47, 87] of
patients and the median survival time was 33 [95% CI 20,
not reached (NR)] months. Combinations of cetuximab
and 5-FU/FA/oxaliplatin have also shown efficacy in the
first-line treatment of mCRC. [28-30] In a study of 43
patients, cetuximab plus FOLFOX-4 led to a response rate
of 72% [95% CI 56, 85]. The median overall survival time
was 30 [95% CI 18, 34] months.[28]. In another study,
among 49 patients receiving cetuximab and FUFOX
Progression-free survival time – including follow-up information on PD Figure 4
Progression-free survival time – including follow-up information on PD.
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(weekly oxaliplatin plus 5-FU/FA), there was a confirmed
response rate of 57% [95% CI 42, 71] and a median over-
all survival time of 28.2 [95% CI 15, NR] months.[30]
Resection of colorectal metastases is recognised as
improving the long-term survival of patients with meta-
static disease, and is the only chance of cure for some
patients. Response rate is a good indicator of resectabil-
ity.[9] In this study, 27% of patients had initially unresect-
able metastatic disease rendered resectable by treatment:
nearly three-quarters of these patients had complete resec-
tions. The results seen in this study support those reported
with a combination of cetuximab and either FOLFOX
(23%)[28] or the AIO schedule of 5-FU/FA and irinotecan
(24%).[17] These secondary resections have to be consid-
ered a good indicator of treatment efficacy. However, esti-
mation of PFS may be difficult with current study designs
where patients discontinued from study treatment for cur-
ative surgery have no assessment of PD and, thus, are cen-
sored at the time of the last on-study tumour assessment.
This was a major reason for conducting sensitivity analy-
ses on PRFS, including reliable follow-up information.
However, even with these modifications, PFS may be
biased because of patients stopping treatment for a pause
because of a good response (15% in this study). These two
points underline the need to develop more sensitive end-
points better able to demonstrate the true benefit of anti-
neoplastic treatments, particularly as targeted therapies
may moderately increase response rates but also improve
the quality of the response and reduce the risk of progres-
sion. While the concept of PRFS must be validated by
other studies, it may help in part to answer these ques-
tions.
Since the completion of this phase I/II trial, the use of
molecular biomarkers to predict response to treatment
has become the focus of much interest. Mutations in the
KRAS gene have been identified in a randomised trial in
mCRC as being predictive of resistance to the IgG2 EGFR-
targeted monoclonal antibody panitumumab [31]. Data
from single-arm studies suggest that KRAS mutations are
also predictive for resistance to cetuximab, both in the
first-line setting and in patients who have failed previous
chemotherapy. [32-35] This has been recently confirmed
Overall survival time Figure 5
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in randomised trials in which cetuximab has been admin-
istered first-line to mCRC patients in combination with
FOLFIRI [36,37] or FOLFOX [38] versus chemotherapy
alone or to chemotherapy-refractory patients in combina-
tion with best supportive care versus best supportive care
alone.[39] This is an important step towards the more
effective tailoring of treatment with cetuximab.
Conclusion
In summary, the results from the present phase I/II study
suggest that the combination of cetuximab and FOLFIRI is
an active and well tolerated treatment option for previ-
ously untreated mCRC that allows secondary resections
without increased morbidity. On the basis of these phase
I/II results, the phase III randomised CRYSTAL trial, com-
paring the efficacy of FOLFIRI (at the same doses used in
this study) with and without cetuximab, was initiated in
EGFR-detectable mCRC. First efficacy data from the CRYS-
TAL trial show good activity and consistency with this
study, with a 47% response rate and a median PFS of 8.9
months in the cetuximab plus FOLFIRI arm: both
response rate and PFS were significantly improved with
the addition of cetuximab to FOLFIRI compared with
FOLFIRI alone.[37]
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